Publication

Article

Supplements and Featured Publications

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin
Volume21
Issue 11 Suppl

eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS

eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS

Evaluated renin-angiotensin-aldosterone system (RAAS) inhibitor drugs and their maximum doses, listed in descending order of observed frequency at index: lisinopril, 40 mg; losartan, 100 mg; valsartan, 320 mg; benazepril, 80 mg; olmesartan, 40 mg; enalapril, 40 mg; spironolactone, 200 mg; irbesartan, 300 mg; ramipril, 10 mg; quinapril, 80 mg; telmisartan, 80 mg; candesartan, 32 mg; captopril, 450 mg; fosinopril, 40 mg; trandolapril, 8 mg; moexipril, 30 mg; aliskiren, 300 mg; eplerenone, 100 mg; perindopril, 8 mg; eprosartan, 800 mg; azilsartan, 80 mg.

Aliskiren/valsartan formulated 150 mg-160 mg (a partial dose of each of 2 RAAS inhibitor drugs) was considered a partial dose (submaximum).

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo